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Summary Psoriatic arthritis is a chronic inflamma-
tory joint disease occurring in a subgroup of patients
suffering from psoriasis. This article gives an overview
of the complexity of psoriatic arthritis, looking at sev-
eral aspects of this heterogeneous disease, such as epi-
demiology, important clinical features and comorbidi-
ties as well as current concepts of the pathophysiology
and subsequent insights in novel treatment targets.
Keywords Psoriatic arthritis · Clinical aspects · Epi-
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Epidemiology
A meta-analysis carried out by Alamanos et al. found
a wide variation in the annual incidence of psori-
atic arthritis (PsA) ranging from 0.1 to 23.1 cases per
100,000 (median 6.4/100,000) inhabitants with large
differences between countries. The mean age at diag-
nosis varied between 40.7 and 52.0 years (median 47.7
years). Prevalence rates also varied between 1 case
per 100,000 (Japan) to 420 per 100,000 (Italian) inhab-
itants [1]. Depending on the definitions used (e.g. di-
agnostic codes, patient self-reporting, rheumatologist
diagnosis and classification criteria) prevalence and
incidence rates vary substantially. Prevalence rates of
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PsA in psoriasis (Pso) patients range from 6% to 41%
[2].
Clinical features
The presence of Pso, inflammatory arthritis and ab-
sence of positive serological tests for rheumatoid
arthritis (RA) are the hallmarks of PsA. In 60–70% of
patients Pso precedes PsA, while in 15–20% arthritis
precedes the onset of Pso. In a small group of patients
(15–20%) the twomanifestations appear within 1 year.
Asymmetrical oligoarthritis is the most common joint
pattern at disease onset [3]. Regarding joint involve-
ment, five groups of inflammatory joint patterns
were defined by Moll and Wright: (1) distal inter-
phalangeal (DIP) predominant arthritis, (2) arthritis
mutilans, (3) symmetrical polyarthritis, (4) asymmet-
rical oligoarthritis or monoarthritis and (5) ankylos-
ing spondylitis predominance [4]. Moll and Wright
proposed asymmetrical oligoarthritis as the most fre-
quent clinical joint pattern of PsA. Studies regarding
the joint pattern distribution in PsA patients vary,
partly because of different definitions of PsA by differ-
ent researchers and partly due to the fact that there is
a probable change of the joint pattern with increasing
disease duration [5]. Axial PsA, with typical features,
such as asymmetrical sacroiliitis, nonmarginal and
asymmetrical syndesmophytes, paravertebral ossi-
fication and involvement of the cervical spine can
be manifested in a broad variety of symptoms [6].
Dactylitis is the clinical term for diffuse inflamma-
tion and swelling of a whole finger or toe and rep-
resents a cardinal finding in PsA patients [4]. The
pathophysiological correlate is the combination of
flexor tenosynovitis, joint effusion and subcutaneous
edema, which is difficult to distinguish clinically and
the diagnosis can therefore be supported by magnetic
resonance imaging (MRI) or ultrasound examinations
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Table 1 Extra-articularmanifestationsofPsA
Gastrointestinal Ocular Cardiovascular Urogenital
Crohn’s disease Uveitis Bundle branch blocks Urethritis
Ulcerative colitis Conjunctivitis Intraventricular blocks Prostatitis
Non-specific colitis Increased arterial stiffness Balanitis
Increased carotid media thickness Cervicitis
Vaginitis
[7]. Inflammation at tendon, ligament, joint capsule
sites and fascia insertion sites into bone is called en-
thesitis and is another hallmark feature of PsA. Pain
and swelling in affected areas are very common and
can be found in approximately half of PsA patients.
Typical entheseal inflammation sites are the Achilles
tendon, the plantar fascia, the greater trochanter tu-
bercle of the femur, the medial femur condyles and
epicondyles of the olecranon [8]. Last, but not least,
nail involvement is much more common with PsA
patients than with Pso patients without arthritis [4].
Clinical presentation of nail changes includes nail
pitting, transverse ridging, yellowish discoloration in
onycholysis, subungual hyperkeratosis, splinter hem-
orrhages and even total destruction of the nail [4,
9].
Of special importance are extra-articular manifes-
tations (EAM) of PsA. They are much more common
than previously thought and seem to be associated
with axial disease. The first study exclusively focus-
ing on EAM in PsA by Peluso et al. in 2015 could
demonstrate an EAM prevalence of 49% in a retro-
spective analysis of 387 PsA patients. Most were male
patients with axial disease and a significantly longer
disease duration than PsA patients without EAM [10].
The most common EAM affect the eyes, the gastroin-
testinal tract, the heart and arteries and the urogenital
system and are summarized in Table 1.
Comorbidities
The most important comorbidities associated with
PsA are those of cardiovascular diseases. An increased
prevalence of cardiovascular risk factors in PsA pa-
tients was shown in several studies and PsA seems
to be associated with obesity, hypertension, insulin
resistance, type II diabetes and hyperlipidemia. Vas-
cular comorbidities include ischemic heart disease,
hypertension, dyslipidemia, atherosclerosis, periph-
eral vascular disease and cerebrovascular disease.
The pathophysiological link seems to be a shared
inflammatory pathway of both metabolic syndrome
and PsA [11, 12]. A large cohort study in the United
Kingdom found an increased incidence of diabetes in
PsA, which may be explained by obesity and lifestyle
factors [13]. Metabolic syndrome and insulin resis-
tance are highly prevalent in PsA patients and there
is a strong association to the severity of inflammatory
disease [14, 15]. Thyroid autoimmunity is increased in
PsA patients, reflected in increased antibodies against
thyroid peroxidase and a hypoechoic thyroid on ul-
trasound examination, especially in female patients
[16].
Pathophysiology
The occurrence of PsA is almost certainly immune-
mediated and probably shares pathogenic mecha-
nisms with Pso. The PsA synovium shows infiltration
with T cells, B cells and macrophages. Clonally ex-
panded CD8+ T cells are frequent in PsA. Plasmacytoid
dendritic cells are thought to play a key role in Pso
and there is some evidence that they are also involved
in PsA. The extensive bone lesions in PsA are consis-
tent with the findings of osteoclastic progenitors in
peripheral blood of PsA patients, as well as upregu-
lation of receptor activator of nuclear factor kappa b
ligand (RANKL) in the synovial lining layer. Cytokines
derived from Th17 are likely to be important in PsA,
given their prominence in Pso and in other forms of
spondylarthritis [17]. Innate immunity also seems to
play a role in the pathogenesis of PsA [18].
Concepts of pathogenesis
Two major hypotheses regarding the pathogenesis of
PsA are under discussion and in the scientific focus
at the moment. One hypothesis considers PsA as
a classical autoimmune disease, the other as a dis-
ease originating from inflammation primarily occur-
ring in the entheseal organ after trauma or physical
stress [19–21].
Classical autoimmune disease
Looking at a classical autoimmune mechanism, with
autoreactive CD8+ T cell clones inducing inflamma-
tion after binding a self-peptide through major histo-
compatibility complex (MHC) class I molecules, PsA
shows certain genetic and immunological features to
support this hypothesis. There is evidence for a sus-
ceptibility to develop PsA in association with certain
MHC class I genes [22]. The observation of CD4+ T cell
depletion and persistence of disease in human im-
munodeficiency virus (HIV) positive PsA patients sug-
gest that PsA is driven by autoreactive CD8+ T cells,
activated through presentation of a self-peptide by
MHC class I susceptibility molecules [23]. Addition-
ally, the absence of autoantibodies and predominance
of CD8+ T cells in joint fluid and in synovial tissue sup-
ports the claim that PsA is an MHC class I-associated
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and CD8+ T cell-mediated autoimmune disease [20].
A relationship of genotype and determining pheno-
types was proposed by FitzGerald et al. in 2015 [20];
therefore, of particular interest may be the possible
pathogenetic explanation of Moll and Wright’s initial
proposed subtypes of PsAwith entheseal, synovial and
axial predominant forms [4].
Enthesitis as primary site of inflammation
In 1998McGonagle et al. proposed the hypothesis that
synovitis in spondylarthropathies may be secondary
to entheseal inflammation, occurring as an epiphe-
nomenon of proinflammatory cytokines and growth
factors from the enthesitis [21]. Subsequent anatomi-
cal studies could show that enthesis, initially declared
to be the insertion site of a muscle or a tendon into
bone, is not that simple to define. The entheseal struc-
ture and physiology seem to be more complex and the
definition of an entheseal organ, including enthesis
and surrounding tissues, such as bursae, periosteal fi-
brocartilage, synovial covered fat pads and sesamoid
bones would fit better in terms of complexity [24, 25].
The close anatomical relationship between synovium
and enthesis is especially prone to mechanical stress.
Microtrauma-induced secretion of immunemediators
seems to promote an altered vascularity of entheses
in elderly, healthy individuals and may furthermore
induce inflammation in predisposed patients, leading
to clinically significant inflammation of joints and de-
velopment of spondylarthropathy or PsA [26, 27]. This
may also be part of the explanation of an epidemiolog-
ical association of higher body mass index (BMI) with
PsA development, with increased mechanical stress
on entheseal structures due to greater body weight
[25].
Further evidence supporting this hypothesis is the
initial site of inflammation in spondylarthropathy
model-related animal models. In 2014 Jacques et al.
could demonstrate a mechanotransduction-associ-
ated origin of enthesitis and new bone formation at
entheseal sites in TNFΔARE mice through activation of
mitogen-activated protein kinase (MAPK) and Erk1/2
signalling pathways [28].
Microbiome
As described in Table 1 an increased risk for devel-
oping Crohn’s disease is evident as a possible EAM
of PsA. Furthermore, a higher incidence of subclinical
gut inflammation has also been described in a sub-
group of PsA patients [29]. A decreased bacterial di-
versity in PsA patients in comparison to Pso patients
and healthy individuals has also been observed [30].
Gut dysbiosis might therefore also be a potential mod-
ulator of autoimmunity.
Obesity
Obesity is an independent risk factor for development
of PsA, as described in the section on risk factors. Low-
grade chronic inflammation is associated with obe-
sity and occurs in many organs and not limited to
adipose tissue. White adipose tissue is an endocrine
active organ secreting soluble mediators, which are
responsible for a proinflammatory environment [31,
32]. Weight loss intervention in Pso patients receiving
biologic agents resulted in an increased efficacy of bi-
ologic agents compared to controls [33]. In a recent
review about autoimmune effects of obesity, Versini et
al. concluded that the proinflammatory state through
increased production of many adipokines including
interleukin (IL)-6, tumor necrosis factor (TNF) alpha,
resistin and leptin, aggravates the development of PsA
and its comorbidities and decreases the efficacy of bi-
ologic therapy [32].
Interleukin 23/Th17 pathway
In PsA patients, a new population of immune cells, IL-
17+CD8+ T-cells, were recently discovered in synovial
fluid where IL-17+CD4-T-cell levels are increased in
PsA synovial fluid in contrast to RA patients. These
cells are comprised mainly of CD8+ cells, are posi-
tively correlated with disease activity (acute phase re-
actants, clinical and radiographic signs of active in-
flammatory joint disease) and may represent an im-
portant subpopulation of immune cells in the patho-
physiology of PsA [34]. In Pso, IL-23 was found to
be fundamentally important in pathogenesis and is
mainly synthesized by dendritic cells of the dermis
and macrophages, which is the main trigger for IL-17
production in the skin, initiating skin inflammation
and acanthosis. Furthermore, pathogen products may
directly stimulate the production of IL-17 [35]. Addi-
tionally, the treatment response of patients induced by
inhibition of this pathway with biologic agents, such
as ustekinumab (anti IL-12/23, European Medicines
Agency EMA approval 01-2009), secukinumab (anti IL-
17A, EMA approval 01-2015), ixekizumab (anti IL-17A,
EMA approval 04-2016) and brodalumab (anti IL-17R,
EMA approval pending) further underlines its impor-
tance in the pathogenesis of PsA [36].
Novel treatment targets
In PsA therapy, conventional disease-modifying anti-
rheumatic drugs (cDMARD) are commonly used
in newly diagnosed diseases [37]. While evidence
from large, well-designed clinical trials is missing,
methotrexate, leflunomide and sulfasalazine are still
regarded as first choice if treatment with non-steroidal
anti-inflammatory drugs (NSAIDs) is insufficient.
Current guidelines favor methotrexate as the first
choice cDMARD, which could show better response
than NSAIDs alone, especially regarding swollen and
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tender joints [38]. Leflunomide was shown to be sig-
nificantly superior to placebo, with effects on periph-
eral arthritis and other PsA manifestations, such as
pain, fatigue, dactylitis and skin disease [39]. Apremi-
last is a new, orally administered, selective inhibitor
of phosphodiesterase 4 (PDE4). The inhibition of
PDE4 increases cyclic adenosine monophosphate,
downregulates the inflammatory cascade and leads to
inhibition of Th1, Th2 and Th17 cytokines. Its clinical
efficacy could be demonstrated in phase 3 trials by
improving signs and symptoms of PsA as well as phys-
ical function [40, 41]. Ustekinumab is a fully human
monoclonal immunoglobulin G1 antibody that binds
the common p40 subunit of IL-12 and IL-23. Inhibi-
tion of IL-12 and IL-23 leads to an inhibition of Th1
and Th17 T-cells leads to an inhibition of important
inflammatory pathways in PsA [36]. In phase 3 trials
ustekinumab especially showed improvement in skin
disease but other factors, such as enthesitis, dactyli-
tis, nail disease, physical function and quality of life
also improve [42]. Another new therapeutic agent is
secukinumab, a human monoclonal IgG1k antibody,
targeting IL-17A, which also has a proinflammatory
role in the pathophysiology of PsA. Recent phase 3
trials in PsA patients showed good efficacy of secuk-
inumab in anti-TNF naive patients as well as patients
who had previously received anti-TNF agents [43].
Conclusion
Psoriatic arthritis resembles a complex inflammatory
joint disease and this review tries to shed light on dif-
ferent aspects of PsA. Besides the psoriatic skin dis-
ease, which can also be difficult to diagnose in the
first place or even be absent in the beginning of the
course of PsA, the clinician has to focus on arthritis
of peripheral joints, as well as axial disease, dactylitis
and enthesitis. PsA is a very heterogeneous disease
with a wide variety of extra-articular manifestations
involving ocular, gastrointestinal, vascular, metabolic
and urogenital symptoms. Comorbidities, such as the
whole spectrum of the metabolic syndrome and thy-
roid autoimmunity, add additional complexity to PsA
management. Our scientific insight into the patho-
physiology of PsA is enlarging and implications on
novel treatment options are evident. In this review, we
hope to highlight some important aspects of PsA and
simultaneously sensitize clinicians to the complexity
of this heterogeneous disease.
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